4-Antibody appoints Dr. Richard Mason as new Chief Executive Officer

01-Oct-2008 - Switzerland

4-Antibody AG announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschäftsführer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence.

Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT’s business development team he was responsible for numerous transactions with major pharmaceutical and biotechnology companies including leading the negotiation of the original antibody co-discovery and co-development agreement with AstraZeneca which subsequently led to AstraZeneca’s acquisition of CAT for $1.3 billion.

Dr. Mason qualified in medicine from the Medical College of St. Bartholomew’s Hospital, University of London. He trained in internal medicine and is a member of the Royal College of Physicians. He also holds a BSc degree in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge.

https://www.bionity.com/en/news/87670/4-antibody-appoints-dr-richard-mason-as-new-chief-executive-officer.html